Today, Johnson & Johnson released its 2025 financial results. Full-year revenue reached $94.2 billion, a 6.0% increase year-over-year ; net income reached $26.8 billion, with diluted earnings per share (EPS) of $11.03, a 90.5% increase year-over-year; adjusted EPS was $10.79, an 8.1% increase year-over-year.

Johnson & Johnson Chairman and CEO Joaquin Duato stated that 2025 will be a pivotal year for the company, marking the beginning of a new era of accelerated growth. The company projects its sales will reach $100 billion by 2026 .

In 2022, Pfizer became the first biopharmaceutical company to reach $100 billion in annual revenue. However, since COVID-19 products accounted for more than half of its sales, its revenue surge lasted only one year.

Four years later, Johnson & Johnson is also about to reach the $100 billion milestone, and this achievement seems to be more sustainable.

Johnson & Johnson's current business consists of two main segments: innovative pharmaceuticals and medical technology.

The innovative pharmaceutical segment contributed $60.4 billion in revenue in 2025, covering six major disease areas: oncology, immunology, neuroscience, cardiovascular, surgery, and eye health.

Its oncology findings are particularly impressive.

DARZALEX (daratumumab) remains a core pillar . The drug is projected to generate $14.4 billion in sales by 2025, with $3.9 billion coming in the fourth quarter, representing a 27% year-over-year increase.

The drug's strong growth is partly attributed to the approval of its subcutaneous formulation, daratumumab Faspro, in 2019. Compared to intravenous infusion, which takes several hours, subcutaneous injection allows patients to complete the administration within minutes.

On the other hand, the exploration of combination therapies may further drive sales growth for this drug. According to data from Johnson & Johnson's Phase 3 MajesTEC-3 clinical trial, in patients with multiple myeloma who have received 1 to 3 lines of prior therapy, the combination therapy of TECVAYLI and DARZALEX significantly outperformed traditional combination therapies. Compared to traditional regimens containing DARZALEX, dexamethasone, and combined with Pomalyst or Velcade, the new combination therapy reduced the risk of death by 54%, and the progression-free survival advantage was as high as 83%.

These data suggest that the combination of DARZALEX FASPRO and TECVAYLI may become a new standard second-line treatment. Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the FDA and has received expedited review designation from the FDA.

In addition, Carvykti (Cedarcis) saw increased sales in second-line treatment, with revenue of $1.887 billion in 2025, a 95.9% increase compared to the same period last year ($963 million).

Other growth drivers for Johnson & Johnson include its blockbuster immunology product Tremfya (guseczyumab), whose sales are projected to grow 40% to approximately $5.2 billion in 2025; and its neuroscience product Spravato, whose sales are projected to grow 57% to $1.7 billion in 2025.

https://news.yaozh.com/archive/46991.html